The relationship between HER2 overexpression and angiogenesis in gastric cancer

被引:20
作者
Ciesielski, Maciej [1 ,2 ]
Szajewski, Mariusz [1 ,2 ]
Peksa, Rafal [3 ]
Lewandowska, Marzena Anna [4 ]
Zielinski, Jacek [5 ]
Walczak, Jakub [1 ]
Szefel, Jaroslaw [1 ,2 ]
Kruszewski, Wieslaw Janusz [1 ,2 ]
机构
[1] Gdynia Oncol Ctr, Dept Surg Oncol, Gdynia, Poland
[2] Med Univ Gdansk, Div Propedeut Oncol, Gdansk, Poland
[3] Med Univ Gdansk, Dept Pathomorphol, Gdansk, Poland
[4] Lukaszczyk Oncol Ctr, IFM, Mol Oncol & Genet Dept, Bydgoszcz, Poland
[5] Med Univ Gdansk, Dept Oncol Surg, Gdansk, Poland
关键词
CD34; ErbB-2; neovascularization; stomach neoplasms; ENDOTHELIAL GROWTH-FACTOR; MICROVESSEL DENSITY; DOUBLE-BLIND; FACTOR-C; EXPRESSION; THERAPY;
D O I
10.1097/MD.0000000000012854
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In gastric cancer, HER2 protein overexpression is considered to be conducive to the higher proliferation activity of the tumor cells. Tumor formation is associated with angiogenesis in order to secure an abundant supply of oxygen and glucose to cancer cells. The aim of the study was to assess if HER2 overexpression is related to higher microvessel density (MVD) in the tumor stroma. The archival samples of primary tumor from 144 consecutive patients that underwent gastric resection for cancer between August 1, 2006 and December 31, 2013 in the Department of Oncological Surgery of Medical University of Gdansk were analyzed. CD34 was used as a marker of MVD in the tumor stroma. Both CD34 and HER2 protein expressions were tested by immunohistochemistry. The assays were unsuccessful to estimate HER2 in 10 cases and CD34 in 14 cases due to technical reasons. The results were obtained for 128 patients. HER2 0 and HER2 1+ were considered negative, while HER2+ and HER2 3+ were recognized as positive. Mean MVD (mean number of vessels in the visual field) was 32.4 (median 29.5). Microvessel density was insignificantly higher in HER2 positive tumors. The slight difference was also seen between IHC 2+ and 3+ groups. The differences did not reach the level of statistical significance. Statistical analysis performed in our study did not reveal the significant relationship between HER2 overexpression on the tumor cells and MVD in the tumor stroma.
引用
收藏
页数:6
相关论文
共 24 条
[1]   Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges [J].
Alameddine, Raafat S. ;
Otrock, Zaher K. ;
Awada, Ahmad ;
Shamseddine, Ali .
CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) :313-324
[2]  
Badescu A, 2012, ROM J MORPHOL EMBRYO, V53, P997
[3]   Gastric biomarkers: a global review [J].
Baniak, Nick ;
Senger, Jenna-Lynn ;
Ahmed, Shahid ;
Kanthan, S. C. ;
Kanthan, Rani .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
[4]   HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology [J].
Bartley, Angela N. ;
Washington, Mary Kay ;
Colasacco, Carol ;
Ventura, Christina B. ;
Ismaila, Nofisat ;
Benson, Al B., III ;
Carrato, Alfredo ;
Gulley, Margaret L. ;
Jain, Dhanpat ;
Kakar, Sanjay ;
Mackay, Helen J. ;
Streutker, Catherine ;
Tang, Laura ;
Troxell, Megan ;
Ajani, Jaffer A. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) :446-+
[5]   HER2-positive gastric cancer [J].
Boku, Narikazu .
GASTRIC CANCER, 2014, 17 (01) :1-12
[6]   The HER2 Gene and HER2 Protein Status and Chromosome 17 Polysomy in Gastric Cancer Cells in Own Material [J].
Ciesielski, Maciej ;
Kruszewski, Wieslaw Janusz ;
Smialek, Urszula ;
Walczak, Jakub ;
Szajewski, Mariusz ;
Szefel, Jaroslaw ;
Wydra, Jacek ;
Kawecki, Krzysztof .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (02) :113-117
[7]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[8]   Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].
Fuchs, Charles S. ;
Tomasek, Jiri ;
Yong, Cho Jae ;
Dumitru, Filip ;
Passalacqua, Rodolfo ;
Goswami, Chanchal ;
Safran, Howard ;
dos Santos, Lucas Vieira ;
Aprile, Giuseppe ;
Ferry, David R. ;
Melichar, Bohuslav ;
Tehfe, Mustapha ;
Topuzov, Eldar ;
Zalcberg, John Raymond ;
Chau, Ian ;
Campbell, William ;
Sivanandan, Choondal ;
Pikiel, Joanna ;
Koshiji, Minori ;
Hsu, Yanzhi ;
Liepa, Astra M. ;
Gao, Ling ;
Schwartz, Jonathan D. ;
Tabernero, Josep .
LANCET, 2014, 383 (9911) :31-39
[9]  
Gasparini G, 2000, Oncologist, V5 Suppl 1, P37
[10]   HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series [J].
Grabsch, Heike ;
Sivakumar, Shivan ;
Gray, Sally ;
Gabbert, Helmut E. ;
Mueller, Wolfram .
CELLULAR ONCOLOGY, 2010, 32 (1-2) :57-65